Data-Driven vs Consensus Diagnosis of MCI

Background and Objectives Given prior work demonstrating that mild cognitive impairment (MCI) can be empirically differentiated into meaningful cognitive subtypes, we applied actuarial methods to comprehensive neuropsychological data from the University of California San Diego Alzheimer's Disease Research Center (ADRC) in order to identify cognitive subgroups within ADRC participants without dementia and to examine cognitive, biomarker, and neuropathologic trajectories. Methods Cluster analysis was performed on baseline neuropsychological data (n = 738; mean age 71.8). Survival analysis examined progression to dementia (mean follow-up 5.9 years). CSF Alzheimer disease (AD) biomarker status and neuropathologic findings at follow-up were examined in a subset with available data. Results Five clusters were identified: optimal cognitively normal (CN; n = 130) with above-average cognition, typical CN (n = 204) with average cognition, nonamnestic MCI (naMCI; n = 104), amnestic MCI (aMCI; n = 216), and mixed MCI (mMCI; n = 84). Progression to dementia differed across MCI subtypes (mMCI > aMCI > naMCI), with the mMCI group demonstrating the highest rate of CSF biomarker positivity and AD pathology at autopsy. Actuarial methods classified 29.5% more of the sample with MCI and outperformed consensus diagnoses in capturing those who had abnormal biomarkers, progressed to dementia, or had AD pathology at autopsy. Discussion We identified subtypes of MCI and CN with differing cognitive profiles, clinical outcomes, CSF AD biomarkers, and neuropathologic findings over more than 10 years of follow-up. Results demonstrate that actuarial methods produce reliable cognitive phenotypes, with data from a subset suggesting unique biological and neuropathologic signatures. Findings indicate that data-driven algorithms enhance diagnostic sensitivity relative to consensus diagnosis for identifying older adults at risk for cognitive decline.

[1]  M. Bondi,et al.  Distinguishing amnestic mild cognitive impairment from HIV-associated neurocognitive disorders. , 2020, The Journal of infectious diseases.

[2]  C. McDonald,et al.  Diagnosing cognitive disorders in older adults with epilepsy , 2020, Epilepsia.

[3]  M. Bondi,et al.  Evidence for the Utility of Actuarial Neuropsychological Criteria Across the Continuum of Normal Aging, Mild Cognitive Impairment, and Dementia , 2020, Journal of Alzheimer's disease : JAD.

[4]  M. Bondi,et al.  Patterns of longitudinal cortical atrophy over 3 years in empirically derived MCI subtypes , 2020, Neurology.

[5]  A. Fagan,et al.  Concordance of Lumipulse cerebrospinal fluid t‐tau/Aβ42 ratio with amyloid PET status , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[6]  Carrie R. McDonald,et al.  Early versus late MCI: Improved MCI staging using a neuropsychological approach , 2019, Alzheimer's & Dementia.

[7]  L. Schneider,et al.  Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need , 2018, Alzheimer's & Dementia.

[8]  J. Hanfelt,et al.  Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center , 2018, Neurobiology of Disease.

[9]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[10]  D. Salmon,et al.  Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study , 2017, Alzheimer's & dementia.

[11]  William T. Hu,et al.  Race modifies the relationship between cognition and Alzheimer’s disease cerebrospinal fluid biomarkers , 2017, Alzheimer's Research & Therapy.

[12]  J. Weuve,et al.  Racial Differences in the Association Between Apolipoprotein E Risk Alleles and Overall and Total Cardiovascular Mortality Over 18 Years , 2017, Journal of the American Geriatrics Society.

[13]  R. Petersen,et al.  NEUROPSYCHOLOGICAL SUBTYPES OF INCIDENT MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY OF AGING , 2017, Alzheimer's & Dementia.

[14]  M. Bondi,et al.  Statistically Derived Subtypes and Associations with Cerebrospinal Fluid and Genetic Biomarkers in Mild Cognitive Impairment: A Latent Profile Analysis , 2017, Journal of the International Neuropsychological Society.

[15]  M. Bondi,et al.  Longitudinal Trajectories of Informant-Reported Daily Functioning in Empirically Defined Subtypes of Mild Cognitive Impairment , 2017, Journal of the International Neuropsychological Society.

[16]  Douglas Galasko,et al.  NPTX2 and cognitive dysfunction in Alzheimer’s Disease , 2017, eLife.

[17]  M. Bondi,et al.  Heterogeneous cortical atrophy patterns in MCI not captured by conventional diagnostic criteria , 2016, Neurology.

[18]  D. Salmon,et al.  "Missed" Mild Cognitive Impairment: High False-Negative Error Rate Based on Conventional Diagnostic Criteria. , 2016, Journal of Alzheimer's disease : JAD.

[19]  M. Bondi,et al.  Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ɛ4 Genotype. , 2016, Journal of Alzheimer's disease : JAD.

[20]  Paul E. Gilbert,et al.  Elevated rates of mild cognitive impairment in HIV disease , 2015, Journal of NeuroVirology.

[21]  M. Bondi,et al.  Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors , 2015, Alzheimer's & Dementia.

[22]  D. Salmon,et al.  Subjective Cognitive Complaints Contribute to Misdiagnosis of Mild Cognitive Impairment Nih Public Access , 2022 .

[23]  Wiesje M van der Flier,et al.  Progression to dementia in memory clinic patients without dementia , 2013, Neurology.

[24]  D. Salmon,et al.  Are Empirically-Derived Subtypes of Mild Cognitive Impairment Consistent with Conventional Subtypes? , 2013, Journal of the International Neuropsychological Society.

[25]  M. Summers,et al.  Absence of a relationship between subjective memory complaint and objective memory impairment in mild cognitive impairment (MCI): is it time to abandon subjective memory complaint as an MCI diagnostic criterion? , 2012, International Psychogeriatrics.

[26]  Leslie M. Shaw,et al.  Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative , 2012, Alzheimer's & Dementia.

[27]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[28]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[29]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[30]  W. Jagust,et al.  Validation of consensus panel diagnosis in dementia. , 2010, Archives of neurology.

[31]  Tania Giovannetti,et al.  The heterogeneity of mild cognitive impairment: A neuropsychological analysis , 2009, Journal of the International Neuropsychological Society.

[32]  M. Bondi,et al.  Heterogeneity in mild cognitive impairment: Differences in neuropsychological profile and associated white matter lesion pathology , 2009, Journal of the International Neuropsychological Society.

[33]  Nathaniel Mercaldo,et al.  The Alzheimer's Disease Centers' Uniform Data Set (UDS): The Neuropsychologic Test Battery , 2009, Alzheimer disease and associated disorders.

[34]  A. Mitchell,et al.  A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. , 2009, Journal of psychiatric research.

[35]  J. Schneider,et al.  Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions , 2005, Neurology.

[36]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[37]  R. Petersen Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[38]  R. Terry,et al.  Position Paper on Diagnostic Criteria for Alzheimer Disease , 1997, Neurobiology of Aging.

[39]  John Q. Trojanowski,et al.  Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[40]  K. Jellinger,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. , 1996, Neurology.

[41]  L A Hansen,et al.  Clinical-neuropathological correlations in Alzheimer's disease and related dementias. , 1994, Archives of neurology.

[42]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[43]  M Haupt,et al.  [Clinical diagnosis of Alzheimer's disease]. , 1988, Deutsche medizinische Wochenschrift.